Momelotinib and Leniolisib: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Leniolisib
Momelotinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased OATP1B1/OATP1B3 substrate exposure
Interaction Deep Dive
Avoid concomitant use of leniolisib with drugs that are both OATP1B1 and OATP1B3 substrates due to a possible increase in systemic exposure of these substrates1.
Why it happens (mechanism)
Inhibition of OATP1B1-mediated efflux transport by leniolisib; inhibition of OATP1B3-mediated efflux transport by leniolisib
Literature reports
1 report — tap to read
a) In a drug interaction study, coadministration of leniolisib and rosuvastatin (substrate of OATP1B1 and OATP1B3) may increase rosuvastatin systemic exposure by 2-fold 1.
Common questions
Can I take Momelotinib and Leniolisib together?
Increased OATP1B1/OATP1B3 substrate exposure Always confirm with your pharmacist or prescriber before making any change.
How serious is the Momelotinib and Leniolisib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Momelotinib or Leniolisib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: JOENJA(R) oral tablets, leniolisib oral tablets. Pharming Healthcare, Inc (per FDA), Warren, NJ, 2025. DailyMed
Keep reading about Leniolisib
Keep reading about Momelotinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist